A nurse talking through a Target Ovarian Cancer leaflet with a woman

MONITOR: A study of maintenance niraparib in clinical practice

Trial at a glance

Open trial

  • Cancer type: Epithelial – high-grade serous and endometrioid | Epithelial – clear-cell
  • Treatment stage: Other
  • Acronym: MONITOR

Multi-centre observational study of maintenance niraparib in treatment of ovarian cancer: UK routine clinical practice experience

Who can take part

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.


You may be able to take part in this clinical trial if you:

  • have ovarian, fallopian tube or primary peritoneal cancer 
  • are already taking niraparib as a maintenance treatment OR
  • are being considered for maintenance treatment with niraparib

This is not an exhaustive list. If you're interested in participating in a clinical trial, you should speak to your doctor about what other criteria might apply.

About the trial

The purpose of this study is to help researchers better understand how niraparib is used in the UK and how well it's tolerated by those taking it.

Niraparib is a type of drug known as a PARP inhibitor. PARP inhibitors are a relatively new class of drugs known as targeted therapies. In this study the researchers wish to collect real time information from clinical practice. This will help them to add more knowledge about niraparib to what they already know from previous clinical trials.

The researchers wish to collect data from participants’ medical records about:

  • date of birth, weight, blood pressure, urine analysis, safety bloods, cancer marker levels (CA125)
  • general details of your medical history
  • date of diagnosis with ovarian cancer and any previous treatment you've received for ovarian cancer
  • information about the stage of your cancer and any surgery for the cancer
  • dates and doses of chemotherapy or other treatment administrations
  • any side effects you might experience during niraparib treatment
  • details of any changes to the treatment prescribed for your ovarian cancer

If you take part in this study, you'll need to:

  • allow researchers access to your medical records while taking niraparib and for up to two years after you stop taking niraparib.
  • complete quality of life questionnaires.

The data will be collected anonymously (you won't be identified).

This information was last reviewed on 12/01/2024. Please note that the status of clinical trials can change at short notice. You should always check with your clinical team which trials may be suitable for your situation.